Antiplatelet agents fail to benefit critically ill adults with COVID-19 - Healio
Compared with no antiplatelet therapy, aspirin and P2Y12 inhibitors did not improve the number of organ support-free days in critically ill patients with COVID-19, according to results of the REMAP-CAP trial published in JAMA.The researchers enrolled 1,557 cr…
Source/Disclosures
Disclosures:
Bradbury reports receiving personal fees from Ablynx, Amgen, Bayer, Bristol Myers Squibb/Pfizer, Eli Lilly, Grifols, Janssen, Novartis and Portola. Please see the… [+5056 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
